PL4135652T3 - Kompozycje rezyniferatoksyny - Google Patents

Kompozycje rezyniferatoksyny

Info

Publication number
PL4135652T3
PL4135652T3 PL21717110.7T PL21717110T PL4135652T3 PL 4135652 T3 PL4135652 T3 PL 4135652T3 PL 21717110 T PL21717110 T PL 21717110T PL 4135652 T3 PL4135652 T3 PL 4135652T3
Authority
PL
Poland
Prior art keywords
resiniferatoxin
compositions
resiniferatoxin compositions
Prior art date
Application number
PL21717110.7T
Other languages
English (en)
Inventor
Andreas Bernkop-Schnürch
Olivier Valdenaire
Thomas Giller
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL4135652T3 publication Critical patent/PL4135652T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL21717110.7T 2020-04-15 2021-04-13 Kompozycje rezyniferatoksyny PL4135652T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169668 2020-04-15
PCT/EP2021/059562 WO2021209450A1 (en) 2020-04-15 2021-04-13 Resiniferatoxin compositions

Publications (1)

Publication Number Publication Date
PL4135652T3 true PL4135652T3 (pl) 2025-03-10

Family

ID=70289711

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21717110.7T PL4135652T3 (pl) 2020-04-15 2021-04-13 Kompozycje rezyniferatoksyny

Country Status (21)

Country Link
US (2) US20230051321A1 (pl)
EP (2) EP4487872A3 (pl)
JP (1) JP7817171B2 (pl)
KR (1) KR20230002560A (pl)
CN (2) CN121512944A (pl)
AU (1) AU2021256948B2 (pl)
BR (1) BR112022020862A2 (pl)
CA (1) CA3172784A1 (pl)
DK (1) DK4135652T3 (pl)
ES (1) ES3004508T3 (pl)
FI (1) FI4135652T3 (pl)
HR (1) HRP20250055T1 (pl)
HU (1) HUE069859T2 (pl)
IL (1) IL297063A (pl)
LT (1) LT4135652T (pl)
MX (1) MX2022012920A (pl)
PL (1) PL4135652T3 (pl)
PT (1) PT4135652T (pl)
RS (1) RS66427B1 (pl)
SI (1) SI4135652T1 (pl)
WO (1) WO2021209450A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228815A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Lyophilized resiniferatoxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040048910A1 (en) * 2002-08-22 2004-03-11 Bove Susan Elizabeth Method of treating osteoarthritis
US7943166B2 (en) * 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
ES2533256T3 (es) * 2004-12-28 2015-04-08 Mestex Ag Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor
EP3219705B1 (en) * 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
EP3359178A4 (en) * 2015-10-06 2019-08-28 Flex Pharma, Inc. METHODS AND COMPOSITIONS FOR UNWANTED OR INORMAL MUSCLE CONTRACTIONS
WO2017087803A1 (en) * 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
JP2018024648A (ja) * 2016-08-05 2018-02-15 日本化薬株式会社 ボルテゾミブを含有する医薬製剤の製造方法
WO2018094262A2 (en) * 2016-11-18 2018-05-24 Mayo Foundation For Medical Education And Research Materials and methods for treating regional pain
KR20200051771A (ko) * 2017-09-11 2020-05-13 소렌토 쎄라퓨틱스, 인코포레이티드 레시니페라톡신 제형
EP3914595A4 (en) * 2019-01-22 2022-11-09 Sorrento Therapeutics, Inc. METHOD OF TREATMENT OF OSTEOARTHRITIS PAIN BY ADMINISTRATION OF RESINIFERATOXIN

Also Published As

Publication number Publication date
RS66427B1 (sr) 2025-02-28
AU2021256948A1 (en) 2022-09-01
US20240382449A1 (en) 2024-11-21
DK4135652T3 (da) 2025-01-20
WO2021209450A1 (en) 2021-10-21
LT4135652T (lt) 2025-02-10
PT4135652T (pt) 2025-01-16
HUE069859T2 (hu) 2025-04-28
EP4135652A1 (en) 2023-02-22
CN115551480B (zh) 2025-11-18
CN121512944A (zh) 2026-02-13
EP4487872A3 (en) 2025-03-26
FI4135652T3 (fi) 2025-01-21
JP2023522537A (ja) 2023-05-31
BR112022020862A2 (pt) 2022-11-29
SI4135652T1 (sl) 2025-03-31
CN115551480A (zh) 2022-12-30
CA3172784A1 (en) 2021-10-21
EP4135652B1 (en) 2024-12-18
IL297063A (en) 2022-12-01
ES3004508T3 (en) 2025-03-12
AU2021256948B2 (en) 2025-06-19
HRP20250055T1 (hr) 2025-03-28
KR20230002560A (ko) 2023-01-05
JP7817171B2 (ja) 2026-02-18
MX2022012920A (es) 2022-11-16
US20230051321A1 (en) 2023-02-16
EP4487872A2 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
ZA202403158B (en) Compositions
GB202013432D0 (en) Compositions
GB202015836D0 (en) Compositions
GB202105461D0 (en) Compositions
GB202102704D0 (en) Compositions
PL4065661T3 (pl) Kompozycje
HUE069859T2 (hu) Gyantaiferatoxin készítmények
GB2610026B (en) Compositions
GB202019952D0 (en) Novel compositions
GB202017863D0 (en) Novel compositions
ZA202210764B (en) Compositions
GB202118081D0 (en) Compositions
GB202117074D0 (en) Compositions
GB202116861D0 (en) Compositions
GB202116386D0 (en) Compositions
GB202116387D0 (en) Compositions
GB202116388D0 (en) Compositions
GB202115617D0 (en) Compositions
GB202114053D0 (en) Compositions
GB202111897D0 (en) Compositions
GB202109945D0 (en) Compositions
GB202109947D0 (en) Compositions
GB202109944D0 (en) Compositions
GB202108656D0 (en) Compositions
GB202114311D0 (en) New compositions